Three large randomized controlled clinical trials are investigating the first-line use of SIR-Spheres® Y-90 resin microspheres in metastatic colorectal cancer (mCRC).
Key endpoints from the SIRFLOX study were reported at ASCO’s Annual Meeting in 2015 and published in the Journal of Clinical Oncology (JCO) in 2016. Overall Survival, the primary endpoint of the FOXFIRE and FOXFIRE Global Study which share a very similar study design to SIRFLOX, are expected in 2017. These data will be combined with the overall survival result from SIRFLOX, representing >1100 subjects, in a pre-planned combined analysis.
In addition to the SIRFLOX and FOXFIRE studies, other clinical studies are currently investigating the treatment of a diverse array of tumor types with SIR-Spheres Y-90 resin microspheres. SIR-Spheres Y-90 resin microspheres are only FDA PMA approved for the treatment of colorectal liver metastases.
SIR-Spheres Y-90 resin microspheres have been extensively used in the treatment of liver metastases from colorectal cancer. Numerous studies, including randomized controlled trials, have been published on the combination of SIR-Spheres Y-90 resin microspheres with first-line chemotherapy, as well as in subsequent lines in combination with chemotherapy or as a single agent for mCRC. View summary of published data for SIR-Spheres Y-90 resin microspheres in the treatment of mCRC